Dear [Name],

We refer to the requested evidence regarding the absence of situations of exclusion as described in the section VI of the [Redacted].

Please find below the comments regarding the documents submitted by you on [Redacted], bearing however in mind that only the evaluation committee is entitled to provide the final assessment and endorsement:

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1. [Redacted]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

[Redacted]

In a situation where Novavax Inc. is [Redacted] we would appreciate if you could provide as a response a statement to that fact.

We rest at your disposal in case of any questions or doubts.

Kind regards

European Commission
From: [Redacted]
Sent: Friday, January 8, 2021 4:21 PM
To: [Redacted]
Cc: [Redacted]
Subject: Fwd: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 — OFFER

Dear [Redacted],

Please see the following email with attachments as follow up to your recent request. We look forward to any updates.

Kind Regards,

Novavax, INC.

Get Outlook for iOS

From: [Redacted]
Sent: Friday, January 8, 2021 10:12 AM
To: [Redacted]
Cc: [Redacted]
Subject: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 — OFFER

Dear [Redacted],

In response to the additional information you requested on [Redacted], we are providing the following in hopes that it meets your needs:

1.

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1.

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

2.
Confidentiality Note
Please be advised that Novavax, Inc. (together with its subsidiaries “Novavax”) is providing this proposal solely for the European Commission (“EC”) to use in the call for tenders SANTE/2020/C3/087 - for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States (the “Project”) and with the understanding that proposal contents will be treated as confidential. The information included in this proposal is confidential and/or private internal information of Novavax and its suppliers that is commercially sensitive and valuable. In accordance with the EC’s procedures and relevant European Union law, we hereby request confidential treatment of all of the materials included in the proposal.

Cheers,

Novavax
Creating Tomorrow’s Vaccines Today

22 Firstfield Road
Gaithersburg, MD 20878
Mobile: [REDACTED]
Email: [REDACTED]
www.novavax.com

********************************************************************
********************************************************************

From: [REDACTED]
Sent: Wednesday, January 6, 2021 10:41 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],

After a first review of the documents submitted by Novavax Inc. it seems that we are missing the following elements:

1. Evidence regarding the financial and economic capacity F1 as described in section 3.2.2. of the Tender Specifications.
2. Evidence regarding the as described in the section VI of the

1. As evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications:

2. As evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

Please note that this is a first, general review of your submission, and we might come back to you with further requests following the assessment by the evaluation committee.

We remain at your disposal in case of any doubts or questions regarding the request.

Kind regards

European Commission
DG Health and Food Safety